A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis.

Loverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L

European journal of obstetrics, gynecology, and reproductive biology18 Dec 2006Cited by 42 (Europe PMC)

PMID17178185DOI10.1016/j.ejogrb.2006.10.034PepBankPUB-17178185

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, triptorelin did not significantly change pain recurrence versus placebo.
In plain wordsAfter endometriosis surgery, triptorelin did not significantly change pain recurrence compared with placebo.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePain recurrence
Study
n = 54
Comparator
Placebo injection after surgery
Outcome group
Pain · Reproductive and sexual health
Studied dose
triptorelin depot-3.75 · intramuscular · 3 monthsAs given in this study (human).
Measurements
Relative risk of pain recurrence
0.94 ratio
triptorelin vs placebo
Relative risk of pain recurrence 95% CI lower limit
0.57 ratio
triptorelin vs placebo
Relative risk of pain recurrence 95% CI upper limit
1.55 ratio
triptorelin vs placebo
P value
1 none
triptorelin vs placebo
Source sentences
Summary
The results of 29 cases treated with triptorelin and 25 that received placebo did not show significant differences in pain recurrence (P=1, RR=0.94, 95% CI=0.57-1.55), endometrioma relapse (P=0.67, RR=1.29, 95% CI=0.66-2.50), and pregnancy rate in infertile women (P=0.80, RR=0.81, 95% CI=0.37-1.80).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial
Summary · context
Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis.
Report a problemFND-1717818501
02HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, triptorelin did not significantly change endometrioma relapse versus placebo.
In plain wordsAfter endometriosis surgery, triptorelin did not significantly change endometrioma relapse compared with placebo.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEndometrioma relapse
Study
n = 54
Comparator
Placebo injection after surgery
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
triptorelin depot-3.75 · intramuscular · 3 monthsAs given in this study (human).
Measurements
Relative risk of endometrioma relapse
1.29 ratio
triptorelin vs placebo
Relative risk of endometrioma relapse 95% CI lower limit
0.66 ratio
triptorelin vs placebo
Relative risk of endometrioma relapse 95% CI upper limit
2.5 ratio
triptorelin vs placebo
P value
0.67 none
triptorelin vs placebo
Source sentences
Summary
The results of 29 cases treated with triptorelin and 25 that received placebo did not show significant differences in pain recurrence (P=1, RR=0.94, 95% CI=0.57-1.55), endometrioma relapse (P=0.67, RR=1.29, 95% CI=0.66-2.50), and pregnancy rate in infertile women (P=0.80, RR=0.81, 95% CI=0.37-1.80).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial
Summary · context
Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis.
Report a problemFND-1717818502
03HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, time to pain recurrence did not differ significantly between triptorelin and placebo during follow-up.
In plain wordsAfter endometriosis surgery, time to pain recurrence did not differ significantly between triptorelin and placebo.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTime to pain recurrence
Study
n = 54
Comparator
Placebo injection after surgery
Outcome group
Pain · Reproductive and sexual health
Studied dose
triptorelin depot-3.75 · intramuscular · 3 monthsAs given in this study (human).
Measurements
P value
0.79 none
time to pain recurrence, triptorelin vs placebo (Mantel-Haenszel logrank)
Source sentences
Summary
Curves of time of pain recurrence and pregnancy during 5-year follow-up did not show significant differences between the two groups (P=0.79 and P=0.51, respectively, using Mantel-Haenzsel logrank test).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial
Summary · context
Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis.
Report a problemFND-1717818504
04HumanRandomized controlled trialEfficacy outcome
In infertile women after endometriosis surgery, triptorelin did not significantly change pregnancy rate versus placebo.
In plain wordsIn infertile women after endometriosis surgery, pregnancy rates did not differ significantly between triptorelin and placebo.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy rate in infertile women
Study
n: not reported in source
Comparator
Placebo injection after surgery
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
triptorelin depot-3.75 · intramuscular · 3 monthsAs given in this study (human).
Measurements
Relative risk of pregnancy in infertile women
0.81 ratio
triptorelin vs placebo
Relative risk of pregnancy in infertile women 95% CI lower limit
0.37 ratio
triptorelin vs placebo
Relative risk of pregnancy in infertile women 95% CI upper limit
1.8 ratio
triptorelin vs placebo
P value
0.8 none
triptorelin vs placebo
Source sentences
Summary
The results of 29 cases treated with triptorelin and 25 that received placebo did not show significant differences in pain recurrence (P=1, RR=0.94, 95% CI=0.57-1.55), endometrioma relapse (P=0.67, RR=1.29, 95% CI=0.66-2.50), and pregnancy rate in infertile women (P=0.80, RR=0.81, 95% CI=0.37-1.80).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial
Summary · context
Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis.
Report a problemFND-1717818503
05HumanRandomized controlled trialEfficacy outcome
After endometriosis surgery, time to pregnancy did not differ significantly between triptorelin and placebo during follow-up.
In plain wordsAfter endometriosis surgery, time to pregnancy did not differ significantly between triptorelin and placebo.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTime to pregnancy
Study
n: not reported in source
Comparator
Placebo injection after surgery
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
triptorelin depot-3.75 · intramuscular · 3 monthsAs given in this study (human).
Measurements
P value
0.51 none
time to pregnancy, triptorelin vs placebo (Mantel-Haenszel logrank)
Source sentences
Summary
Curves of time of pain recurrence and pregnancy during 5-year follow-up did not show significant differences between the two groups (P=0.79 and P=0.51, respectively, using Mantel-Haenzsel logrank test).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial
Summary · context
Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis.
Report a problemFND-1717818505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.